CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021

Rhea-AI Summary

CohBar, Inc. (NASDAQ: CWBR) plans to release its third quarter 2021 financial results after market closure on November 15, 2021. The company, engaged in developing mitochondria-based therapeutics for chronic diseases, will host a conference call at 5:00 p.m. ET to discuss these results and provide a business update. Interested participants can dial in using the provided numbers. An audio replay will be available from 8:00 p.m. ET on November 15 through December 6, 2021.

Positive

• The lead compound, CB4211, successfully completed a Phase 1a/1b clinical trial in August 2021.
• CohBar has four preclinical programs advancing towards clinical trials, including a peptide targeting idiopathic pulmonary fibrosis.

Negative

• None.

Company to host conference call at 5:00 p.m. ET

MENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2021 financial results after the market closes on Monday, November 15, 2021. Management will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

Details for the Conference Call:

Date: November 15, 2021
Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference Audio

• Dial-in U.S. and Canada: (844) 825-9789
• Dial-in International: (412) 317-5180
• Conference ID No.: 10161656
  

For individuals participating in the Investor Call, please call into the conference audio approximately 10 minutes prior to its start.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on November 15, 2021, through 11:59 p.m. Eastern Time on December 6, 2021. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 10161656. The audio recording will also be available at www.cohbar.com during the same period.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company’s lead compound, CB4211, which is under development for the treatment of NASH and obesity, completed a successful Phase 1a/1b clinical trial in August 2021. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies with the goal of filing an IND and initiating a First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

For additional company information, please visit www.cohbar.com.

Contacts:

Jordyn Tarazi
Director of Investor Relations
CohBar, Inc.
(650) 445-4441
Jordyn.tarazi@cohbar.com 

FAQ

When will CohBar release its Q3 2021 financial results?

CohBar will release its third quarter 2021 financial results after market close on November 15, 2021.

What time is the CohBar conference call scheduled for?

The conference call is scheduled for 5:00 p.m. ET on November 15, 2021.

How can I access the audio replay of the CohBar conference call?

The audio replay will be available starting at 8:00 p.m. ET on November 15, 2021, through December 6, 2021.

What is the main focus of CohBar's research?

CohBar focuses on developing mitochondria-based therapeutics to treat chronic and age-related diseases.

What is the status of CohBar's lead compound CB4211?

CB4211 successfully completed a Phase 1a/1b clinical trial in August 2021.